Tamfrex XL

Quick links

Choose a section

Quick links to important sections

Advertisements

Tamfrex XL

Selected form

Advertisements
Advertisements

Overview of Tamfrex XL

Quick Facts

Property Description
Active ingredient Tamsulosin Hydrochloride
Form Prolonged-release hard capsule (XL/MR)
Pharmacological class Selective \alpha1-adrenergic receptor antagonist (Alpha blocker)
Common use Relieving functional symptoms of the lower urinary tract
Origin Synthetic

Identity and Pharmacological Classification

Tamfrex XL is a synthetic, prescription-only medication primarily intended for use in adult men. Its single, specific active ingredient is Tamsulosin Hydrochloride. Pharmacologically, it is categorized as a selective \alpha1-adrenergic receptor antagonist, commonly known as an alpha blocker. This classification is defined by its targeted mechanism, as the compound is designed to selectively interact with specific biological pathways. This compound is clinically recognized for its selectivity, an attribute that differentiates it from older, less targeted alpha blockers. This feature allows the medicine to focus its action primarily on the smooth muscle tissue of the lower urinary tract.


Composition and The Meaning of "XL"

The medication is an oral dosage form, presented as a hard capsule containing modified-release pellets of the active substance. The designation "XL" in Tamfrex XL signifies an extended-release or prolonged-release formulation, a key feature that simplifies the regimen. This proprietary extended-release system is designed to ensure the Tamsulosin Hydrochloride is delivered gradually and consistently into the bloodstream. The prolonged-release mechanism achieves a stable therapeutic concentration of the compound, which supports a simplified, once-daily administration.


General Purpose of This Alpha Blocker

The general purpose of Tamfrex XL is to relieve functional symptoms associated with lower urinary tract issues by reducing tissue resistance. This is achieved because the drug acts to facilitate the relaxation of smooth muscles located primarily in the prostate gland and the neck of the bladder. By easing the tension in these specific muscular structures, the primary physiological effect is a reduction in the resistance encountered by the urinary outflow tract. This modification of muscle tone helps improve the mechanical flow of urine, which is the typical goal when treating restricted flow in this anatomical area.

Advertisements

What side effects are possible with Tamfrex XL?

Possible Side Effects and Safety Information

The safety profile for Tamfrex XL (tamsulosin hydrochloride) is officially classified by government regulatory authorities based on observed frequencies and affected organ systems. The majority of reported effects are related to the drug's activity as a selective alpha blocker.


Official Adverse Reaction Classification

Adverse reactions are documented according to System-Organ Classes (SOCs) and frequency bands, ranging from common to very rare, based on clinical trial data and post-marketing surveillance.

Classification Examples of Documented Effects
Common Dizziness, Headache, Asthenia, Nausea, Abnormal Ejaculation, Rhinitis.
Uncommon Orthostatic Hypotension (postural dizziness), Palpitations, Rash, Pruritus, Constipation, Vomiting.
Rare/Very Rare Syncope (fainting), Angioedema (swelling), Priapism, Stevens-Johnson Syndrome.

Dizziness and Abnormal Ejaculation are among the most frequently reported events. Safety documents note that symptoms of Orthostatic Hypotension are detected more frequently, particularly at the beginning of treatment.


Serious Adverse Reactions and Safety Constraints

Regulatory documents highlight several serious adverse reactions, including the risk of Priapism (a persistent, painful erection) and severe hypersensitivity reactions like Angioedema and Stevens-Johnson Syndrome.

For patients undergoing cataract or glaucoma surgery, the risk of Intraoperative Floppy Iris Syndrome (IFIS) is a specific safety consideration. The medicine is formally contraindicated in individuals with known severe hepatic impairment and in those with a history of orthostatic hypotension.

Advertisements

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Tamfrex XL (Tamsulosin Hydrochloride) is primarily characterized by the exaggeration of its pharmacological effect, leading to severe complications. The main documented clinical manifestation is acute hypotension (significantly low blood pressure). Other presentations observed in cases of acute overdosage include vomiting and diarrhoea. A severe outcome associated with profound hypotension is syncope (fainting).


Overdose Management and Emergency Actions Details from Regulatory Information
Urgent Medical Action Required Immediate medical attention must be sought in the event of acute hypotension.
Antidote Availability No specific antidote is known; treatment is purely symptomatic and supportive. Dialysis is unlikely to be effective.
Supportive Measures Cardiovascular support must be provided and maintained. This involves placing the patient in a supine position to help restore blood pressure. Volume expanders (intravenous fluids) or vasopressors may be administered if basic measures are insufficient. For large quantity ingestions, procedures like gastric lavage or administration of activated charcoal and an osmotic laxative may be considered.
Monitoring Requirements Continuous monitoring of blood pressure and heart rate is necessary. Additionally, renal function should be monitored throughout the management process.

The regulatory profile strictly defines the required response as symptomatic and supportive treatment, focusing on immediate cardiovascular stabilization due to the risk of severe hypotensive effects.

Advertisements

Therapeutic Uses of Tamfrex XL

What Tamfrex XL Treats: Main Uses and Benefits

Tamfrex XL (tamsulosin) is commonly used to help manage the signs and symptoms associated with conditions that involve significant physiological strain. This medicine is relevant across therapeutic domains where short-term symptomatic assistance is needed. It contributes to easing the overall symptom load for patients experiencing distressing symptoms.

Therapeutic Scope and Benefits

This medicine is generally applied in addressing condition categories characterized by episodic or fluctuating symptom patterns. It helps address groups of symptoms that may appear suddenly or intensify over time, providing temporary assistance in symptom stabilization that assists with maintaining functional stability. It is used in areas where short-term symptom management is appropriate. It is considered relevant in clinical settings where symptoms cluster into patterns requiring supportive management in contexts marked by increased discomfort or tension.

“Provides support that helps ease the overall burden of symptoms.”

Quick Fact: Relief for Urinary Discomfort

Tamfrex XL may help patients cope more steadily with difficult episodes and helps improve day-to-day comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus Drug Information
Advertisements

Eligibility and Restrictions for Use

Who Can and Cannot Use Tamfrex XL

Official regulatory documents define the eligible population for Tamfrex XL (tamsulosin) based strictly on age, gender, and specific health conditions. The medicine is formally indicated only for use in adult men aged 18 years and older.

Contraindicated and Restricted Populations

Certain patients must not use this medicine. Use is contraindicated in patients with a known hypersensitivity to tamsulosin hydrochloride or any of its components, and in those with a history of orthostatic hypotension or severe hepatic insufficiency. The product is not indicated for use in women or pediatric patients (under 18 years) as safety and efficacy have not been established in these groups.

Conditions Requiring Caution

Use is restricted or requires caution for specific patient groups:

  • Organ Impairment: Patients with severe hepatic impairment or end-stage renal disease (CrCl < 10 mL/min) have not been studied, and use is restricted.
  • Surgical Risk: Initiation of therapy is not recommended in patients scheduled for cataract or glaucoma surgery due to potential surgical complications.
  • Allergies: Caution is warranted for patients with a known sulfa (sulfonamide) allergy.
Advertisements

What should I know about interactions with other medicines?

Tamfrex XL Interactions with other medicines and products

Tamfrex XL (tamsulosin) should not be used in combination with certain medicines due to potential for significant drug interactions.

Pharmacokinetic Interactions

Tamfrex XL is metabolized primarily by the liver enzymes CYP3A4 and CYP2D6. Co-administration with drugs that inhibit these enzymes can increase tamsulosin levels in the bloodstream, raising the potential for adverse effects, particularly low blood pressure.

Interacting Product Category Example Medicines Interaction Outcome
Strong CYP3A4 Inhibitors Ketoconazole Increased tamsulosin exposure (AUC/Cmax). This combination should not be used in patients identified as CYP2D6 poor metabolizers. Use with caution in all other patients.
Moderate CYP3A4 Inhibitors Erythromycin Increased tamsulosin exposure. Use with caution.
Strong CYP2D6 Inhibitors Paroxetine Small increase in tamsulosin exposure; generally not considered clinically significant.
Cimetidine (H2-antagonist) Increased tamsulosin plasma levels.
Diclofenac, Warfarin (NSAID/Anticoagulant) May increase the elimination rate of tamsulosin.

Pharmacodynamic Interactions

Co-administering Tamfrex XL with other medicines that lower blood pressure carries a risk of enhanced hypotensive effects, which may result in symptomatic low blood pressure (e.g., dizziness or fainting).

  • Other Alpha-1 Adrenoceptor Antagonists: Combination with other alpha-blockers is generally not recommended.
  • Phosphodiesterase-5 (PDE5) Inhibitors (e.g., sildenafil, tadalafil): Caution is advised due to the potential for symptomatic hypotension.
  • Other Antihypertensive Drugs: Use with caution due to the theoretical risk of an additive reduction in blood pressure.

Patients should inform their healthcare provider of all prescription, over-the-counter medicines, and supplements they are taking to properly manage potential interactions.

Advertisements

Mechanism of Action

Selective Alpha-1 Receptor Blockade

Tamsulosin acts as a selective competitive antagonist against the alpha-1 adrenergic receptors (alpha1-ARs), primarily the alpha1A and alpha1D subtypes. This mechanism involves interrupting the signaling of the sympathetic nervous system by blocking the binding site for the endogenous neurotransmitter norepinephrine, thereby preventing receptor activation and subsequent muscle contraction.


Modulation of Smooth Muscle Tone

The core function of this blockade is that the compound acts within the smooth muscle contractile cascade. By suppressing the receptor signal, the drug prevents the release of intracellular calcium ( Ca^2+) in the muscle cells of the prostate and bladder neck. The resulting smooth muscle relaxation decreases the functional resistance within the urinary outflow tract.


Sustained Receptor Affinity and Limitations

Tamsulosin exhibits a relatively slow dissociation rate from its target receptors, which supports a persistent blockade of the target receptors and continuous modulation of smooth muscle tone. This action is purely functional (relaxation) and does not engage mechanisms that would affect the size or physical mass of the prostate tissue.

Advertisements

Dosage and Administration Information

How to Use Tamfrex XL

This section outlines the standardized usage protocol for Tamfrex XL (Tamsulosin Hydrochloride).


Administration Scope

Instruction Detail
Route of administration Oral
Dosing schedule Initial and standard dose is 0.4 mg once daily. The dose may be increased to a maximum of 0.8 mg once daily for adult patients who do not respond after 2 to 4 weeks of treatment at the lower dose.
Timing in relation to meals Must be taken approximately one-half hour following the same meal each day to maintain consistent drug absorption.
Age-group rules Use is restricted to adult men; it is not indicated for the pediatric population.
Handling restrictions The prolonged-release capsule must be swallowed whole and must not be crushed, chewed, broken, or opened.
Interrupted therapy If administration is discontinued for several days, it is required to restart therapy at the 0.4 mg once-daily dose.

Procedural Summary

Use Protocol: The protocol centers on the oral administration of the extended-release capsule once daily. The dose is typically initiated at 0.4 mg and is sustained for long-term symptom management. The key procedural constraint involves taking the medicine specifically after a meal and strictly avoiding any alteration of the capsule's structure. Established guidance dictates that dose adjustments (titration to 0.8 mg) must only occur after a period of assessment, and interrupted therapy must always be re-initiated at the starting 0.4 mg dose. This structure ensures adherence to the drug's intended pharmacokinetic profile.

Advertisements

Recent Clinical Evidence

Evidence for use in Lower Urinary Tract Symptoms (LUTS)

The evidence for Tamfrex XL (Tamsulosin Hydrochloride) is primarily based on Randomized Controlled Trials (RCTs) and Systematic Reviews examining symptomatic patterns related to Lower Urinary Tract Symptoms (LUTS) suggestive of an enlarged prostate. These studies focused on measurable changes in patient-reported scoring systems, such as the International Prostate Symptom Score (IPSS), alongside objective measures of urinary function like maximum urinary flow rate.


Comparing Tamfrex XL in Clinical Trials

Research protocols involved comparing the medicine against an inactive agent, or placebo, to assess measured differences between the active group and the control group. Studies also monitored parameters when the medicine was evaluated as part of research that included other established pharmacological agents for LUTS. Study reports documented a noticeable pattern of symptomatic change, known as the placebo response, even in the inactive groups.


Long-term Studies and Maintenance of Outcomes

While the initial RCTs focused on short-term research (typically 12 weeks to 6 months), there are records of long-term open-label extension studies that tracked patients for up to several years. These extensions monitored outcomes over extended intervals. However, data are still emerging regarding the full characterization of sustained symptomatic and functional outcomes under rigorous, blinded conditions over a patient's lifetime.


Evidence in Specific Patient Populations

The primary research evaluated adult men diagnosed with Moderate to Severe LUTS. Evidence was evaluated in these populations, including men across different age ranges, particularly those over 50 years old. Studies also explored use of the medicine as part of a combination regimen with treatments for co-existing conditions.


Research Gaps and Unanswered Questions

Key limitations documented in the research include the limited follow-up durations in the most rigorously designed trials, meaning the long-term effects are not fully established. Research also describes patterns indicating that a portion of the studied population did not exhibit measured changes, and subgroup findings regarding non-response are uncertain.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Tamfrex XL (FAQ)


Q: Is Tamfrex XL the same type of medication as other common treatments for the condition?

A: Tamfrex XL is classified as an alpha-1 adrenergic receptor antagonist, commonly known as an alpha blocker. Official documents indicate that this mechanism of action is distinct from other classes of medication sometimes used for the same condition, such as 5-alpha reductase inhibitors (5-ARIs). It works by targeting specific receptors to facilitate muscle relaxation.


Q: Can Tamfrex XL cause fatigue or sleepiness?

A: Studies and official product information indicate that the active ingredient may cause sleepiness (somnolence) and difficulty falling or staying asleep (insomnia). The commonly reported side effects also include weakness (asthenia), which is a feeling of reduced strength or energy. Information regarding the medicine's effect should be reviewed.


Q: Are there any common supplements or vitamins that might interact with Tamfrex XL?

A: Regulatory documents mention that the active ingredient in Tamfrex XL is metabolized by certain liver enzymes, which may be affected by various substances. For this reason, official sources advise patients to inform their healthcare provider of all supplements, vitamins, and herbal products they are taking due to the potential for interaction.


Q: How long does it usually take before I might notice the effects of Tamfrex XL?

A: Data from clinical studies indicate that the maximum clinical increases in urinary flow rates were observed after up to eight weeks of dosing. This indicates that the observed effects during research were not immediate.


Q: Does taking Tamfrex XL affect my ability to drive or operate machinery?

A: Official warnings state that the medicine may cause dizziness or drowsiness. Warnings caution that individuals should not drive, operate machinery, or perform tasks requiring mental alertness until the medicine's effects are understood.


Q: Are there any specific foods I should avoid while using Tamfrex XL?

A: The official product information specifies that Tamfrex XL must be taken approximately one-half hour following the same meal each day to ensure consistent drug absorption. However, the labeling does not list any specific foods that must be avoided while using the medication.


Q: Can older adults use Tamfrex XL?

A: The medicine is formally indicated only for use in adult men. While no overall differences in safety or effectiveness were observed compared to younger patients in official studies, official sources indicate that a greater sensitivity of some older adults cannot be ruled out.


Q: Does official information describe the use of Tamfrex XL if I have kidney issues?

A: Official information indicates that the use of this medicine has not been studied in patients with end-stage renal disease (very severe kidney impairment), and its use is restricted in this population. However, no dosing adjustments are generally required for patients with other degrees of renal impairment.


Q: Is it okay to drink alcohol in moderation while on Tamfrex XL?

A: Regulatory information indicates that consuming alcohol can increase the blood pressure-lowering effect of Tamfrex XL. This enhanced effect may increase the risk of experiencing dizziness or lightheadedness (symptomatic hypotension).


Q: What is the difference between Tamfrex XL and the regular Tamfrex version?

A: The designation 'XL' signifies an extended-release or prolonged-release formulation. This modified delivery system ensures the active ingredient is released gradually and consistently over a 24-hour period, which supports a simplified once-daily dosing regimen.


Q: Are there any warnings about taking Tamfrex XL if I have a heart condition?

A: The medicine is known to cause orthostatic hypotension (a drop in blood pressure when standing up) and is formally contraindicated in patients with a history of this condition. Because of its effect on blood pressure, this may be a consideration for those with certain pre-existing heart conditions.


Q: Will Tamfrex XL interfere with routine lab test results?

A: Official documentation states that treatment with the active ingredient had no significant effect on Prostate-Specific Antigen (PSA) levels for up to 12 months. Unlike some other medications for the condition, no adjustment to PSA values is typically needed for monitoring.


Q: Does Tamfrex XL lose its effectiveness over time?

A: Official long-term open-label extension studies monitored the maintenance of outcomes for patients for several years. However, research documents note that the full characterization of sustained outcomes under rigorously designed conditions is still being established.


Q: Are there specific symptoms that warrant calling a doctor immediately while taking Tamfrex XL?

A: Official sources describe several serious adverse reactions associated with this class of drug. These include Priapism (a persistent, painful erection), severe swelling of the face or throat (Angioedema), and severe skin reactions like Stevens-Johnson Syndrome. These are classified as serious adverse reactions.


Q: What is the purpose of the 'inactive ingredients' listed in Tamfrex XL?

A: Inactive ingredients are components added for purposes other than the primary therapeutic effect. According to official labeling, these components provide the physical structure of the capsule or are necessary to create the extended-release mechanism of the medicine.


Q: Are there any long-term health concerns associated with taking Tamfrex XL?

A: Official records show that long-term open-label extension studies monitored patient outcomes for up to several years. Nevertheless, regulatory documents indicate that the full characterization of sustained symptomatic and functional outcomes is not fully established in the most rigorous, long-duration trials.


Q: What information is available about stopping the use of Tamfrex XL?

A: The official protocol centers on managing therapy interruptions. If administration is discontinued or interrupted for several days, instructions require that therapy must be restarted with the initial 0.4 mg once-daily dose.


Q: Is it true that Tamfrex XL can affect sleep patterns?

A: Official documentation of the active ingredient includes the potential for causing difficulty falling or staying asleep (insomnia). Changes in sleep patterns are part of the effects that may be documented.


Q: Does Tamfrex XL require any special monitoring by a doctor?

A: Official warnings advise that patients should be screened for prostate cancer prior to initiating treatment. Additionally, monitoring for symptoms of orthostatic hypotension is advised when starting the medicine or increasing the dose.

Advertisements

How should Tamfrex XL be stored and disposed of?

How to Store and Dispose of Tamfrex XL

Official Storage Conditions

Tamfrex XL (tamsulosin hydrochloride) must be stored at controlled room temperature, generally between 20 C and 25 C (68 F to 77 F).

To ensure protection from moisture, the medication must be kept in its original package. For the prolonged-release capsule to function correctly, the product must remain intact; therefore, the capsules must not be crushed, chewed, or opened. The labeled shelf life for some formulations is three years under these specified conditions.

Handling and Disposal

All medicine must be stored out of the sight and reach of children to ensure safety. When disposal is necessary, any unused or expired Tamfrex XL must be discarded in accordance with local requirements for pharmaceutical waste. The official labeling does not specify any special requirements for hazardous or environmental waste handling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Tamfrex XL found in:

A-Z Index: